A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Gilteritinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms CHRYSALIS
  • Sponsors Astellas Pharma; Astellas Pharma Global Development
  • Most Recent Events

    • 08 Jan 2018 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 12 Dec 2017 Results of an exploratory analysis from the study, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top